Comparative effectiveness research for antipsychotic medications: How much is enough

Health Affairs

Volumn 28, Issue 5, 2009, Pages

  Meltzer, David O ^a   Basu, Anirban ^a   Meltzer, Herbert Y ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE;

ACCURACY; ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG RESEARCH; HEALTH CARE POLICY; SCHIZOPHRENIA; UNCERTAINTY;

ANTIPSYCHOTIC AGENTS; COMPARATIVE EFFECTIVENESS RESEARCH; COST-BENEFIT ANALYSIS; HEALTH POLICY; HUMANS; UNITED STATES;

EID: 70349211955     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.28.5.w794     Document Type: Article

References (57)

1. R. Tandon and W.W. Fleischhacker, "Comparative Efficacy of Antipsychotics in the Treatment of Schizophrenia: A Critical Assessment," Schizophrenia Research 79, nos. 2-3 (2005): 145-155.
2. This paper uses the commonly used terms "first-generation antipsychotics" and "second-generation antipsychotics," which are sometimes called "typical" and "atypical" antipsychotic drugs. H.Y. Meltzer, "Atypical Antipsychotic Drugs Have Their Merits," Lancet 373, no.9668 (2009): 1007.
3. J.M. Kane, "Tardive Dyskinesia Rates with Atypical Antipsychotics in Adults: Prevalence and Incidence," Journal of Clinical Psychiatry 65, no.9 Supp. (2004): 16-20.
4. We excluded clozapine because of its risk of causing dangerously low white blood cell counts (agranulocytosis), which has limited its approved use for patients who do not respond sufficiently to treatment with other antipsychotic drugs or who cannot tolerate the drug's greater potential to cause movement disorders.
5. R.S. Kahn et al., "Effectiveness of Antipsychotic Drugs in First-Episode Schizophrenia and Schizophreniform Disorder: An Open Randomised Clinical Trial," Lancet 371, no.9618 (2008): 1085-1097;
6. H.Y. Meltzer, "Focus on the Metabolic Consequences of Long-Term Treatment with Olanzapine, Quetiapine and Risperidone: Are There Differences?" International Journal of Neuropsychopharmacology 8, no.2 (2005): 153-156;
7. N.D. Woodward et al., "A Meta-Analysis of Neuropsychological Change to Clozapine, Olanzapine, Quetiapine, and Risperidone in Schizophrenia," International Journal of Neuropsychopharmacology 8, no.3 (2005): 457-472;
8. and L. Lagnado, "Prescription Abuse Seen in U.S. Nursing Homes,"Wall Street Journal, 4 December 2007.
9. J. Lieberman et al., "Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia," New England Journal of Medicine 353, no.12 (2005): 1209-1223. (Pubitemid 41345943)
10. R.A. Rosenheck et al., "Cost-Effectiveness of Second Generation Antipsychotics and Perphenazine in a Randomized Trial of Treatment for Chronic Schizophrenia," American Journal of Psychiatry 163, no.12 (2006):2080-2089.
11. S. Lewis and J. Leiberman, "CATIE and CUtLASS: Can We Handle the Truth?" British Journal of Psychiatry 192, no.3 (2008): 161-163;
12. R.A. Rosenheck et al., "Rethinking Antipsychotic Formulary Policy," Schizophrenia Bulletin 34, no.2 (2008): 375-380;
13. J.A. Lieberman and J.K. Hsiao, "Interpreting the Results of the CATIE Study," Psychiatric Services 57, no.1 (2006): 139;
14. and J.A. Lieberman, "What the CATIE Study Means for Clinical Practice," Psychiatric Services 57, no.8 (2006): 1075. (Pubitemid 44204898)
15. Rosenheck et al., "Cost-Effectiveness";
16. J. Lieberman (Plenary Lecture, International Congress of Schizophrenia Research, Colorado Springs, April 2007);
17. J. Davis, N. Chen, and I.D. Glick, "Issues That May Determine the Outcome of Antipsychotic Trials: Industry Sponsorship and Extrapyramidal Side Effects," Neuropsychopharmacology 33, no.5 (2008): 971-975;
18. and S. Leucht et al., "Second-Generation versus First-Generation Antipsychotic Drugs for Schizophrenia: A Meta-Analysis," Lancet 373, no.9657 (2009): 31-41.
19. R.A. Rosenheck et al., CATIE Investigators' Educational Series (2007);
20. R.A. Rosenheck, "Comparing Schizophrenia Drugs" (editorial), New York Times, 21 September 2005;
21. and S.B. Soumerai and M.R. Law, "Cost-Effectiveness of Schizophrenia Pharmacotherapy," American Journal of Psychiatry 164, no.4 (2007): 678.
22. P.B. Jones et al., "Randomized Controlled Trial of the Effect on Quality of Life of Second- versus First-Generation Antipsychotic Drugs in Schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1)," Archives of General Psychiatry 63, no.10 (2006): 1079-1087;
23. and Kahn et al., "Effectiveness of Antipsychotic Drugs."
24. P.J. Neumann, Using Cost-Effectiveness to Improve Health Care (New York: Oxford University Press, 2004).
25. The CATIE Investigators' Educational Series recommends that states' public health officials consider restricting coverage of second-generation antipsychotics.
26. R. Tandon et al., "World Psychiatric Association Pharmacopsychiatry Section Statement on Comparative Effectiveness of Antipsychotics in the Treatment of Schizophrenia," Schizophrenia Research 100, nos. 1-3 (2008): 20-38.
27. H.J. Möller, "Are the New Antipsychotics No Better Than the Classical Neuroleptics? The Problematic Answer from the CATIE Study," European Archives of Psychiatry and Clinical Neuroscience 255, no.6 (2005): 371-372;
28. Soumerai and Law, "Cost-Effectiveness";
29. and N.H. Covell, M.T. Finnerty, and S.M. Essock, "Implications of CATIE for Mental Health Services Researchers," Psychiatric Services 59, no.5 (2008): 526-529.
30. B.J. Kinon et al., "Standard and Higher Dose of Olanzapine in Patients with Schizophrenia or Schizoaffective Disorder: A Randomized, Double-Blind, Fixed-Dose Study," Journal of Clinical Psychopharmacology 28, no.4 (2008): 392-400;
31. H.Y. Meltzer et al., "A Randomized, Double-Blind Comparison of Clozapine and High-Dose Olanzapine in Treatment-Resistant Patients with Schizophrenia," Journal of Clinical Psychiatry 69, no.2 (2008): 274-285;
32. H.Y. Meltzer and W.V. Bobo, "Interpreting the Efficacy Findings in the CATIE Study: What Clinicians Should Know," CNS Spectrum 11, no.7, supp. 7 (2006): 14-24;
33. and P.J. Weiden, "Discontinuing and Switching Antipsychotic Medications: Understanding the CATIE Schizophrenia Trial," Journal of Clinical Psychiatry 68, no.1 Supp. (2007): 12-19. (Pubitemid 46256966)
34. Soumerai and Law, "Cost-Effectiveness." An example of algorithms is the International Psychopharmacology Algorithm Project (home page: http://www.ipap.org).
35. J. Tiihonen et al., "Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of Patients in Community Care after First Hospitalisation due to Schizophrenia and Schizoaffective Disorder: Observational Follow-Up Study," BMJ 333, no.7561 (2006): 224-231;
36. and Kahn et al., "Effectiveness of Antipsychotic Drugs."
37. Specifically, the standard gamble technique assigns a utility weight between 0 and 1 to a health state by finding the highest risk of immediate death that people will accept in order to be restored to perfect health instead of the health state being rated.
38. W. Dale et al., "Predicting Utility Ratings for Joint Health States from Single Health States in Prostate Cancer: Empirical Testing of Three Alternative Theories," Medical Decision Making 28, no.1 (2008): 102-112.
39. Rosenheck et al., "Cost-Effectiveness."
40. The problem has to dowith the uses of transformed data. See Technical Appendix 1, "Detailed Discussion of Data Transformation, Part I," online at http://content.healthaffairs.org/cgi/content/full/hlthaff.28.5.w794/ DC2.
41. Further discussion of this problem is available in Technical Appendix 1, "Detailed Discussion of Data Transformation, Part II," "Detailed Discussion of Data Transformation, Part I," ibid.
42. Rosenheck et al., "Cost-Effectiveness."
43. Lewis and Lieberman, "CATIE and CUtLASS."
44. Lewis and Lieberman, "CATIE and CUtLASS."Ibid.;
45. Tiihonen et al., "Effectiveness of Antipsychotic Treatments";
46. Tandon et al., "World Psychiatric Association Pharmacopsychiatry Section Statement";
47. and Jones et al., "Randomized Controlled Trial of the Effect on Quality of Life."
48. K. Claxton et al., "Bayesian Value-of-Information Analysis: An Application to a Policy Model of Alzheimer's Disease," International Journal of Technology Assessment in Health Care 17, no.1 (2001): 38-55;
49. and National Institute for Health and Clinical Excellence, "Guidance on the Removal of Wisdom Teeth," Technology Appraisal Guidance no. 1 (London: NICE, March 2000).
50. D. Meltzer, "Addressing Uncertainty in Medical Cost-Effectiveness Analysis: Implications of Expected Utility Maximization for Methods to Perform Sensitivity Analysis and the Use of Cost-Effectiveness Analysis to Set Priorities for Medical Research," Journal of Health Economics 20, no.1 (2001): 109-129;
51. and K. Claxton, "The Irrelevance of Inference: A Decision-Making Approach to the Stochastic Evaluation of Health Care Technologies," Journal of Health Economics 18, no.3 (1999): 341-364.
52. Claxton et al., "Bayesian Value of Information Analysis."
53. For more detail, see Technical Appendix 2, "Details on Calculation Method," online as in Note 22.
54. These means and variances come from simulated distributions of mean QALYs and mean annual costs; the full distributions can be seen in Technical Appendix 3, online as in Note 22.
55. R.S. Braithwaite et al., "What Does the Value of Modern Medicine Say about the $50,000 per Quality-Adjusted Life-Year Decision Rule?" Medical Care 46, no.4 (2008): 349-356.
56. It is interesting that the typical antipsychotics are less than 50 percent likely to be cost-effective yet appear to be the cost-effective choice. This is possible because the average net benefit if they are cost-effective is greater than the average negative net benefit if they are not cost-effective.
57. See Technical Appendix 2, online as in Note 22.